Unknown PHASE2 INTERVENTIONAL 1-arm NCT06285149

Tace With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B Patients

Prospective Single-arm, Single-center Exploratory Clinical Study on Efficacy and Safety of Interventional Therapy Combined With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B Patients

Sponsor: Henan Cancer Hospital

Conditions HCC

Interventions Icaritin

Updated 4 times since 2024 Last updated: Feb 22, 2024 Started: Mar 1, 2024 Primary completion: Dec 1, 2024 Completion: Jun 1, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06285149, this PHASE2 trial focuses on HCC and remains ongoing. Sponsored by Henan Cancer Hospital, it has been updated 4 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Feb 2026 — Present [monthly]

Unknown PHASE2

Status: Not Yet Recruiting → Unknown
Sep 2024 — Feb 2026 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Mar 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Henan Cancer Hospital

Data source: Henan Cancer Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.